Maravai LifeSciences' TriLink Partners with Avantor to Boost Nucleic Acid Product Accessibility

TriLink BioTechnologies Partners with Avantor to Enhance Nucleic Acid Product Accessibility

TriLink BioTechnologies, a subsidiary of Maravai LifeSciences, announces a strategic partnership with Avantor, Inc. This collaboration aims to significantly enhance the availability of TriLink's innovative nucleic acid-based products across Europe, the Middle East, and Africa (EMEA). By leveraging Avantor's extensive distribution network, TriLink intends to streamline the ordering process and reduce delivery times for European customers, ultimately improving access to its cutting-edge technologies. This partnership aligns with TriLink's commitment to meet the growing demands of the biopharmaceutical market and ensure that researchers can efficiently utilize high-quality reagents and services.

The partnership will facilitate the distribution of a wide range of TriLink’s nucleic acid products, including CleanCap® capping analogs, catalog mRNAs, and a selection of over 150 modified and unmodified nucleotides. Additionally, powerful in vitro transcription (IVT) enzymes like CleanScribe® RNA polymerase will be available for research use or produced under good manufacturing practices (GMP). The collaboration signifies a vital step in TriLink's strategy to broaden its market presence within the EMEA region, a critical area for advancements in life sciences and biotechnology.

Becky Buzzeo, Chief Commercial Officer at TriLink, underscores the importance of this partnership in expanding access to their state-of-the-art nucleic acid technologies throughout Europe. As demand for innovative biotechnological solutions grows, this initiative is designed to support transformative therapeutic research and development. As TriLink continues to advance its portfolio of mRNA-based therapeutics, vaccines, and diagnostics, the enhanced logistics and distribution capabilities provided by Avantor will play a crucial role in meeting the needs of researchers and companies in the rapidly evolving biotechnological landscape.

In addition to improving logistics, the partnership will introduce TriLink's products on Avantor's MarketSource e-commerce platform, making it easier for customers in the EMEA region to access the necessary reagents. This move not only optimizes the supply chain but also contributes to the company's mission of fostering innovation in life sciences by ensuring that high-quality nucleic acid products are readily available to a growing customer base.

As TriLink BioTechnologies and Avantor embark on this collaboration, both companies look forward to fostering advancements in scientific research and supporting the biopharmaceutical industry through improved access to essential biotechnological products. The partnership signifies a commitment to enhancing customer satisfaction and expanding the reach of TriLink's innovative solutions in the global marketplace.